Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Gerresheimer’s glass and plastic prefillable syringes will come with an innovative, integrated, passive syringe safety solution, acquired through an exclusive licence from West Pharmaceutical Services.

Gerresheimer to Launch Innovative Syringe Safety Solution through Exclusive Licence from West

The company has entered into a settlement agreement with generic-drug companies to resolve patent litigation. 


Eli Lilly Resolves Patent Litigation Over Cialis

The acquisition will add recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio

Sanofi Acquires Protein Sciences

ABEC increases the maximum capacity of its Custom Single Run Bioreactors to 4000 L, doubling the industry standard.

ABEC Releases 4000-L Single-Use Bioreactor

GE Healthcare’s Dharmacon business and CordenPharma contract manufacturing enter a strategic collaboration to accelerate the oligonucleotide development process.

CordenPharma, GE Healthcare Partner to Speed Development

Recro Gainsville expands its tableting capacity with the addition of a tablet press and film coater.

Recro Gainesville Adds Manufacturing Capacity

Lilly will provide up to $52 million in funding for research, making this Purdue’s largest strategic corporate collaboration

Eli Lilly and Purdue University Launch Five-Year Collaboration

A Supreme Court decision and improvements in analytical processes may speed the biosimilar approval process.


Biosimilars Overcome Legal and Analytical Hurdles

SOBI003 is a chemically modified variant of a recombinant human sulfamidase product candidate, using Sobi’s proprietary glycan modification technology.

SOBI003 Granted Orphan Drug Designation for MPS IIIA Treatment

Samsung BioLogics signs $55.5 million agreement to manufacture tildrakizumab for Sun Pharma.